Richard D. Carvajal, MD: Marlana, this has been a great conversation. Let’s close with future directions.
2021
Uveal Melanoma: Sequencing Therapy
Richard D. Carvajal, MD: You presented nice work trying to tease out the potential confounding effects of post-progression therapies.
Tebentafusp for Uveal Melanoma: Adverse Events
Marlana M. Orloff, MD: When I first started introducing the mechanism of tebe [tebentafusp], I mentioned that gp100 [glycoprotein 100] is in 2 places—on the tumor and in the skin on the melanoma site.
Uveal Melanoma: Patient Candidacy for Tebentafusp
Richard D. Carvajal, MD: We have the 202 [IMCgp100-202] study, which was basically untreated patients, a clear survival advantage.